NCT07251062 2025-11-26
A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 2/3 Not yet recruiting
Clinical Trials
13 trialsNCT06907602 2025-04-02
ONTRESCC
Peking Union Medical College Hospital
Phase 2/3 Recruiting
NCT06861777 2025-03-11
Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3 Not yet recruiting
NCT06138028 2024-07-24
Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer
Qingdao Central Hospital
Phase 2/3 Recruiting
NCT06354530 2024-04-09
A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Army Medical Center of PLA
Phase 2/3 Recruiting
NCT03600831 2024-01-09
Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma
Huai'an First People's Hospital
Phase 2/3 Completed
NCT04973306 2022-06-30
iCROSS
Shanghai Zhongshan Hospital
Phase 2/3 Recruiting
NCT05213312 2022-06-15
Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC
Shanghai Zhongshan Hospital
Phase 2/3 Unknown
NCT03623737 2022-06-07
Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC
National Taiwan University Hospital
Phase 2/3 Unknown
NCT02272699 2021-03-18
Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma
Peking University
Phase 2/3 Withdrawn
NCT00861094 2015-12-18
Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer
UNICANCER
Phase 2/3 Completed
NCT00509561 2012-12-18
Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer
Wales Cancer Trials Unit
Phase 2/3 Unknown
NCT01402180 2011-07-26
Nimotuzumab
Fudan University
Phase 2/3 Unknown